What raises the risk of lung cancer, and why does early detection matter? Our latest blog breaks down the basics.
Cizzle Bio is advancing CIZ1B, a biomarker blood test for early lung cancer, coming soon to U.S. healthcare providers.
Read more: https://t.co/C1CHjYJ7WD
Its great to see @CizzlePlc in the @yorkshirepost! This Yorkshire company is starting to get noticed, and it deserves it.
Let's get this life-changing lung cancer test out into the world and start saving lives! #CIZ
Grail's stock dropped 50% after the UK NHS trial (142K people) failed to hit targets. Their DNA test spots only 22% of early-stage lung cancers—vs. CIZ's simple, low-cost blood test has a 95% detection rate.
Lung cancer, the #1 cancer killer, claims ~125K US lives yearly—more than colon, breast & prostate combined.
#Biotech #CancerScreening #CIZ
https://t.co/wAh3GvXjAZ
Cizzle Bio has submitted an NIH grant proposal with top research partners to advance our biomarker blood test for early lung cancer.
We are building a diagnostic platform designed for clinical adoption and market growth.
https://t.co/owPpBd9CKF
Lung cancer is rising in younger adults, and many are diagnosed too late.
A new ASCO article urges better early detection tools.
Cizzle Bio is advancing a patented biomarker blood test to catch lung cancer early and make detection more accessible.
https://t.co/050nARFWSk
🚨 Big step for early cancer detection:
We secured £150K to roll out its breakthrough lung cancer blood test in the UK 🇬🇧
✅ Non-invasive
✅ Detects cancer before symptoms
✅ Supports NHS early diagnosis targets
https://t.co/5WNWzbJbTd
#LungCancer#Biotech#CizzleBiotech
Today we are at #JPM2025 in San Francisco.
As a company committed to revolutionising early cancer detection, we are excited to participate in discussions shaping the future of diagnostics and healthcare innovation. DM us to schedule a meeting!
#Healthcare#JPMHealthcare#CIZ
Market cannot continue to ignore #ciz much longer.
Lab accreditation coming.
Marketing events coming.
Funding sorted.
Launch due April in North America.
Simple fast testing with replication of lab results.
Eventually launch in China.
Stake in BIO and royalty agreements.
🎥 Video Interview : Cizzle Biotechnology Expanding into USA and Transforming Cancer Screening 🚨
👉 Watch the full video now to learn how Cizzle is making waves in the fight against lung cancer: https://t.co/GaeZQH45K1
#CizzleBiotechnology#CancerScreening
4 / 5
• BIO expects to register its first US CLIA accredited lab with the FDA for the CIZ1B LDT test in September 2024.
· BIO plan to achieve CLIA Certification for the LDT test in November 2024, with a full product launch by April 2025
#CureCancer#CancerResearchSavesLives
3 / 5
• We received an initial $100,000 fee from BIO for exclusive negotiation rights, will receive a further $300,000 payment upon signing a binding agreement, and $2.3 million in advance royalties over 30 months.
#CIZ#EarlyLungCancerDiagnosis#Cancer
2 / 5
· Selected by US cancer centre to participate in a clinical evaluation using our CIZ1B biomarker test thanks to Cizzle Bio Inc.
· We extended our research agreement with the @UniOfYork to be a #biomarker partner in the evaluation and continue new product development.
1 / 5
We are making big strides with our CIZ1B test, a simple blood test that is highly associated with early stage #lungcancer.
Here's what's happening: